Drugs / Bodewell Calming Cream
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05566262 | Nov 2023 → Feb 2027 expected | atopic eczema | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bodewell Calming Cream | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05566262 ↗ |
| Route | Topical | “Bodewell will be applied topically twice a day to all active lesions.” NCT05566262 ↗ |